The National Academy of Sciences released a groundbreaking report, “The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.” The report states that there is conclusive evidence that marijuana can be used as a medicine. The report did not find clinical evidence for all conditions marijuana treatment is often associated with, but it recognizes its efficacy for treating many medical conditions such as “chronic pain in adults…chemotherapy-induced nausea and vomiting and multiple sclerosis spasticity symptoms.”
“This report is vindication for all the many researchers, patients and healthcare providers who have long understood the benefits of medical marijuana,” said Michael Collins, Deputy Director of National Affairs at the Drug Policy Alliance. “To have such a thorough review of the evidence conclude that there are benefits to medical marijuana should boost the case for federal reform. It also underlines how out of touch the DEA and other marijuana reform opponents are when they claim otherwise.”
The report is skeptical of marijuana’s benefit in treating some medical conditions, such as cancer. Nonetheless, the report, “a comprehensive review of the current evidence regarding the health effects of using cannabis and cannabis-derived products,” is a strong rebuke to many of those who have denied that marijuana can be used as medicine. It also found evidence that suggests “smoking cannabis does not increase the risk for cancers often associated with tobacco use – such as lung and head and neck cancers.”
Currently, 28 U.S. states have medical marijuana laws, and 16 additional states have CBD laws (a non-psychoactive component of medical marijuana). Last summer, the DEA announced that it would not reschedule marijuana. The NAS report notes that “There are specific regulatory barriers, including the classification of cannabis as a Schedule I substance, that impede the advancement of cannabis and cannabinoid research.”
Just this week, President-elect Trump’s candidate for Attorney General, Senator Jeff Sessions, was asked at his nomination hearing about what he would do about medical marijuana patients who are following state law but violating federal law. Sessions gave a wishy-washy answer, acknowledging the Department of Justice’s limited resources but ominously saying, “I won’t commit to not enforcing federal law.”
Medical marijuana amendments routinely passed the Republican-controlled House and Republican-controlled Senate Appropriations Committee over the past three years, while an amendment to end federal marijuana prohibition outright failed by just nine votes last year in the House.
The uncertainty over medical marijuana and how the Trump administration will approach the issue is expected to drive efforts at reform in Congress. Advocates anticipate the reintroduction of the CARERS Act, a bill that would let states set their own medical marijuana policy without federal interference, and would remove many research barriers.
The above article is for EDUCATIONAL PURPOSES ONLY.
FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of CBD. We believe this constitutes a fair use of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this web page is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.
Care Beyond is a distributor of content sometimes supplied by third parties and other users. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by third parties, including information providers, users, or others, are not those of Care Beyond, but are those of the respective author(s) or distributor(s). The content does not necessarily reflect the views, policies or practices of the Care Beyond, or its agencies, officials or employees.
Any reference on the Care Beyond website, social media sites, and mobile applications to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, is not an endorsement or recommendation. Any reference shall not be used for advertising or product endorsement purposes.
Care Beyond is not responsible for the contents of any off-site pages linked from the Care Beyond's website, social media sites, and mobile applications. As a user of the Care Beyond's website, social media sites, and mobile applications, you specifically acknowledge that the Care Beyond and its contributors are not liable for any defamatory, offensive, or illegal conduct of other users, links, or third parties and that the risk of injury from all off-site content mentioned here rests entirely with you, the user.
Links from the Care Beyond's website, social media sites, and mobile applications to other sites do not constitute an endorsement from or for Care Beyond. These links are provided as a convenience for users and as an informational service only. As a user, it is your responsibility to determine the content and usefulness of information you find on other sites.